



#3

SEQUENCE LISTING

<110> PEPTIDE THERAPEUTICS LIMITED et al

<120> A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES
THAT COVALENTLY MODIFY SUBSTRATE MOLECULES

<130> 39200A/JMD/NT

<140> PCT/GB98/03259

<141> 1998-10-30

<150> GB 9722818.3

<151> 1997-10-30

<160> 21

<170> PatentIn Ver. 2.1

<210> 1

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: formula for a
library comprising natural and/or unnatural amino
acid residues or peptidomimetics

<220>

<221> UNSURE

<222> (1)

<223> Xaa at position 1 is any natural or unnatural
amino acid residue or peptidomimetic and is
repeated x times

<220>

<221> UNSURE

<222> (2)

<223> Xaa at position 2 is a non-degenerate modifiable
natural or unnatural amino acid residue or
peptidomimetic

<220>

<221> UNSURE

<222> (3)

<223> Xaa at position 3 is any natural or unnatural
amino acid residue or peptidomimetic and is
repeated y times.

<220>

<221> UNSURE

<222> (1)..(3)

<223> x and y are each independently 0 or an integer; (x
+ y) = (n - 1); and n = an integer from 3 to 8,
preferably 5

<400> 1
Xaa Xaa Xaa
1

<210> 2
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: formula for
library used to identify protein kinase inhibitor
molecules

<220>
<221> UNSURE
<222> (1)
<223> Xaa at position 1 is any natural or unnatural
amino acid residue or peptidomimetic and is
repeated x times

<220>
<221> UNSURE
<222> (3)
<223> Xaa at position 3 is any natural or unnatural
amino acid residue or peptidomimetic and is
repeated y times

<220>
<221> UNSURE
<222> (1)..(3)
<223> x and y are each independently 0 or an integer; $(x + y) = (n-1)$; and n = an integer from 3 to 8,
preferably 5

<400> 2
Xaa Tyr Xaa
1

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: consensus
peptide substrate for ZAP-70

<220>
<221> UNSURE
<222> (1)
<223> Biotin-epsilon-aminohexanoic acid is linked to the
aspartic acid residue at position 1

<220>

<221> UNSURE
<222> (8)
<223> Leucine at position 8 is Norleucine

<400> 3
Asp Glu Glu Asp Tyr Phe Glu Leu
1 5

<210> 4
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: general
formula for peptide library containing substrates
for protein serine or serine/threonine kinase
enzyme

<220>
<221> UNSURE
<222> (1)
<223> Xaa at position 1 is any natural or unnatural
amino acid residue or peptidomimetic and is
repeated x times

<220>
<221> UNSURE
<222> (3)
<223> Xaa at position 3 is any natural or unnatural
amino acid residue or peptidomimetic and is
repeated y times

<220>
<221> UNSURE
<222> (1)..(3)
<223> x and y are each independently 0 or an integer; (x
+ y) = (n - 1); and n = an integer from 3 to 8,
preferably 5

<400> 4
Xaa Ser Xaa
1

<210> 5
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
used to amplify the coding sequence for human
ZAP-70 amino acids 306-615 from Jurkat T cell cDNA

<400> 5

ccgggatccg ccatgcccacat ggacacgagc gtgtat

36

<210> 6

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer
used to amplify the coding sequence for human
ZAP-70 amino acids 306-615 from Jurkat T cell cDNA

<400> 6

gggggatcct cagtgggtggt ggtgggtggtg ggcacaggca gcctcagcct tctgtgt

57

<210> 7

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence of
phosphorylated motif identified by screen of
library peptides

<400> 7

Asp Glu Glu Asp Tyr

1

5

<210> 8

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence of
phosphorylated motif identified by screen of
library peptides

<400> 8

Asp Glu Glu Tyr Phe

1

5

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sequence of
phosphorylated peptide motif identified by screen
of library peptides

<400> 9

Asp Glu Tyr Glu Phe

1

5

<210> 10
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> UNSURE
<222> (5)
<223> Leucine at position 5 is Norleucine

<220>
<223> Description of Artificial Sequence: sequence of
phosphorylated motif identified by screen of
library peptides

<400> 10
Asp Tyr Phe Glu Leu
1 5

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for Syk

<400> 11
Asp Glu Glu Asp Tyr
1 5

<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for Syk

<400> 12
Asp Glu Glu Tyr Asp
1 5

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for Syk

<400> 13
Asp Glu Tyr Glu Asp
1 5

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for Syk

<400> 14
Asp Tyr Glu Glu Val
1 5

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> UNSURE
<222> (5)
<223> Leucine at position 5 is Norleucine

<220>
<223> Description of Artificial Sequence: peptide
identified as preferred substrate for Syk

<400> 15
Tyr Ser Ile Ile Leu
1 5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for CSK

<400> 16
Asp Glu Glu Glu Tyr
1 5

<210> 17
<211> 5

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for CSK

<400> 17
Asp Glu Glu Tyr Phe
1 5

<210> 18
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for CSK

<400> 18
Asp Glu Tyr His Asn
1 5

<210> 19
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for CSK

<400> 19
Asp Tyr His Leu Phe
1 5

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: peptide
identified as a preferred substrate for CSK

<400> 20
Tyr Pro Ile Glu Val
1 5

<210> 21
<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: peptide
identified as active site substrate recognition
substrate for v-Abl

<400> 21

Ser Tyr Phe His Glu

1

5